Cathie Wood’s ARK sells DraftKings stock and buys CRISPR Therapeutics

On October 9th, 2026, Ark Invest’s ETF, managed by Cathie Wood, detailed their daily trading activities across multiple funds. A key transaction involved the sale of 397,016 shares of DraftKings Inc. from the ARKW and ARKF ETFs, valued at around $7.89 million. This followed a series of recent sales by ARK in DraftKings. Another substantial move saw the sale of 57,911 shares of CareDx, Inc., totaling $3.60 million, through the ARKG ETF, continuing a pattern of consistent selling in CareDx.

Conversely, ARK increased its stake in CRISPR Therapeutics AG by adding 21,487 shares to the ARKG ETF, with the transaction valued at $1.08 million, reflecting ARK’s ongoing interest in the gene-editing sector. The company also bought 7,210 shares of Guardant Health, Inc., valued at $1.19 million, and expanded its position in Nurix Therapeutics, Inc., purchasing 56,096 shares for $1.24 million.

Other notable trades included the sale of 22,276 shares of Space Exploration Technologies Corp for $3.58 million, and the acquisition of 48,171 shares of Intellia Therapeutics, Inc. for $606,954. ARK also made smaller investments in Alamar Biosciences Inc, Beam Therapeutics Inc, and Compass Pathways PLC, while selling shares of Advanced Micro Devices, Alphabet Inc, and Shopify Inc. These trades illustrate ARK’s strategic approach, focusing on innovative companies across various sectors while adapting positions in response to market trends and strategic goals.